About: BOLD-100

Property	Value
dbo:abstract	BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is a ruthenium-based anti-cancer therapeutic in clinical development. As of November 2021, BOLD-100 was being tested in a Phase 1b clinical trial in patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 is being developed by Bold Therapeutics Inc. (en) BOLD-100，即反式四氯二(1H-吲唑)合钌(III)酸钠，是一种临床开发中的钌基的抗癌药。截至2021年11月，在晚期胃肠道癌患者中，BOLD-100正与化疗方案联合进行1b期临床试验。它由Bold治疗有限公司开发。 BOLD-100具有八面体结构，赤面上由两个反式吲唑配体和四个氯离子配体，它的阳离子为钠，且含有痕量的铯。 (zh)
dbo:casNumber	197723-00-5
dbo:chEBI	176975
dbo:drugbank	75535930
dbo:pubchem	9806062
dbo:wikiPageID	69346844 (xsd:integer)
dbo:wikiPageLength	8679 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1094070711 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Chlorides dbc:Ruthenium_complexes dbc:Experimental_cancer_drugs dbr:Apoptosis dbc:Indazoles dbc:Ruthenium(IV)_compounds dbr:KP1019 dbr:RuCl3 dbr:Reactive_oxygen_species dbr:Unfolded_protein_response dbr:FOLFOX dbr:GRP78
dbp:caption	BOLD-100 Chemical Structure (en)
dbp:casNumber	197723 (xsd:integer)
dbp:chebi	176975 (xsd:integer)
dbp:drugbank	75535930 (xsd:integer)
dbp:iupacName	sodium trans-[Tetrachlorobisruthenate] (en)
dbp:pubchem	9806062 (xsd:integer)
dbp:routesOfAdministration	Intravenous (en)
dbp:smiles	C1=CC=C2CC=NN2.C1=CC=C2CC=NN2.[Na+].Cl[Ru]Cl (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	YGDDGJPSWMFECS-UHFFFAOYSA-J (en)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Short_description
dcterms:subject	dbc:Chlorides dbc:Ruthenium_complexes dbc:Experimental_cancer_drugs dbc:Indazoles dbc:Ruthenium(IV)_compounds
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is a ruthenium-based anti-cancer therapeutic in clinical development. As of November 2021, BOLD-100 was being tested in a Phase 1b clinical trial in patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 is being developed by Bold Therapeutics Inc. (en) BOLD-100，即反式四氯二(1H-吲唑)合钌(III)酸钠，是一种临床开发中的钌基的抗癌药。截至2021年11月，在晚期胃肠道癌患者中，BOLD-100正与化疗方案联合进行1b期临床试验。它由Bold治疗有限公司开发。 BOLD-100具有八面体结构，赤面上由两个反式吲唑配体和四个氯离子配体，它的阳离子为钠，且含有痕量的铯。 (zh)
rdfs:label	BOLD-100 (en) BOLD-100 (zh)
owl:sameAs	wikidata:BOLD-100 dbpedia-zh:BOLD-100 https://global.dbpedia.org/id/GaBRZ
prov:wasDerivedFrom	wikipedia-en:BOLD-100?oldid=1094070711&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:BOLD-100
is dbo:wikiPageRedirects of	dbr:KP-1339 dbr:IT-139
is dbo:wikiPageWikiLink of	dbr:RAPTA dbr:NAMI-A dbr:Bernhard_Keppler dbr:Ruthenium_anti-cancer_drugs dbr:KP-1339 dbr:KP1019 dbr:IT-139
is foaf:primaryTopic of	wikipedia-en:BOLD-100